<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
  <ref-type name="Journal Article">17</ref-type>
  <contributors>
    <authors>
      <author>Müller, Stephan A.</author>
      <author>Shmueli, Merav D.</author>
      <author>Feng, Xiao</author>
      <author>Tüshaus, Johanna</author>
      <author>Schumacher, Neele</author>
      <author>Clark, Ryan</author>
      <author>Smith, Brad E.</author>
      <author>Chi, An</author>
      <author>Rose-John, Stefan</author>
      <author>Kennedy, Matthew E.</author>
      <author>Lichtenthaler, Stefan F.</author>
    </authors>
    <subsidiary-authors>
      <author>AG Lichtenthaler</author>
    </subsidiary-authors>
  </contributors>
  <titles>
    <title>The Alzheimer’s disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130</title>
    <secondary-title>Molecular neurodegeneration</secondary-title>
  </titles>
  <periodical>
    <full-title>Molecular neurodegeneration</full-title>
  </periodical>
  <publisher>Biomed Central</publisher>
  <pub-location>London</pub-location>
  <isbn>1750-1326</isbn>
  <electronic-resource-num>10.1186/s13024-023-00596-6</electronic-resource-num>
  <language>English</language>
  <pages>13</pages>
  <number>1</number>
  <volume>18</volume>
  <abstract>The protease BACE1 is a major drug target for Alzheimer's disease, but chronic BACE1 inhibition is associated with non-progressive cognitive worsening that may be caused by modulation of unknown physiological BACE1 substrates.To identify in vivo-relevant BACE1 substrates, we applied pharmacoproteomics to non-human-primate cerebrospinal fluid (CSF) after acute treatment with BACE inhibitors.Besides SEZ6, the strongest, dose-dependent reduction was observed for the pro-inflammatory cytokine receptor gp130/IL6ST, which we establish as an in vivo BACE1 substrate. Gp130 was also reduced in human CSF from a clinical trial with a BACE inhibitor and in plasma of BACE1-deficient mice. Mechanistically, we demonstrate that BACE1 directly cleaves gp130, thereby attenuating membrane-bound gp130 and increasing soluble gp130 abundance and controlling gp130 function in neuronal IL-6 signaling and neuronal survival upon growth-factor withdrawal.BACE1 is a new modulator of gp130 function. The BACE1-cleaved, soluble gp130 may serve as a pharmacodynamic BACE1 activity marker to reduce the occurrence of side effects of chronic BACE1 inhibition in humans.</abstract>
  <notes>
    <note>CC BY ; </note>
  </notes>
  <label>PUB:(DE-HGF)16, ; 0, ; </label>
  <keywords>
    <keyword>Mice</keyword>
    <keyword>Humans</keyword>
    <keyword>Animals</keyword>
    <keyword>Alzheimer Disease: drug therapy</keyword>
    <keyword>Amyloid Precursor Protein Secretases</keyword>
    <keyword>Cytokine Receptor gp130: therapeutic use</keyword>
    <keyword>Aspartic Acid Endopeptidases</keyword>
    <keyword>Interleukin-6</keyword>
    <keyword>Nerve Tissue Proteins</keyword>
    <keyword>IL-6 receptor subunit beta</keyword>
    <keyword>IL-6R</keyword>
    <keyword>Secretase</keyword>
    <keyword>Shedding</keyword>
    <keyword>Trans-signaling</keyword>
    <keyword>VCAM1</keyword>
    <keyword>Amyloid Precursor Protein Secretases</keyword>
    <keyword>Cytokine Receptor gp130</keyword>
    <keyword>Aspartic Acid Endopeptidases</keyword>
    <keyword>Interleukin-6</keyword>
    <keyword>BACE1 protein, human</keyword>
    <keyword>Sez6 protein, mouse</keyword>
    <keyword>Nerve Tissue Proteins</keyword>
    <keyword>Bace1 protein, mouse</keyword>
  </keywords>
  <accession-num/>
  <work-type>Journal Article</work-type>
  <dates>
    <pub-dates>
      <year>2023</year>
    </pub-dates>
  </dates>
  <accession-num>DZNE-2023-00286</accession-num>
  <year>2023</year>
  <custom2>pmc:PMC9942414</custom2>
  <custom6>pmid:36810097</custom6>
  <urls>
    <related-urls>
      <url>https://pub.dzne.de/record/255485</url>
      <url>https://doi.org/10.1186/s13024-023-00596-6</url>
    </related-urls>
  </urls>
</record>

</records>
</xml>